To the Editor,

Due to the clinical similarity of COVID-19 with other flu-like syndromes, patients were tested for other pathogens of respiratory tract infections (RTIs) as well, especially in the very first weeks of the epidemic. In those weeks, we used the multiplex polymerase chain reaction (PCR) Biofire FilmArray Pneumonia panel (BioFire Diagnostics, bioMerieux, I) allowing the detection of 33 respiratory pathogens with a run-time of 1 h. Herewith, we report the etiological pattern of RTIs diagnosed at the Amedeo di Savoia Hospital, regional reference centre for infectious diseases of Piedmont, North-Western Italy, during the first weeks of the COVID-19 epidemic. We retrospectively reviewed clinical and microbiologic records generated for routine clinical practice (ethical approval not required) from 162 consecutive patients \[93 male, median age of 64 years (range 12-93\] from February 12^th^ to March 31^st^ 2020 with respiratory symptoms who were screened with FilmArray (FA) and RT-PCR for COVID-19 diagnosis, after multiple sample collection in COPAN UTM transport medium (Copan, I). For the detection of SARS-CoV-2 specific RNA, a multiplex Real Time PCR Kit (Liferiver, CHN) was used (detection limit: 1×10^3^ copies/ml). The kit measures simultaneously 3 viral genes: SARS-CoV-2 gene E, N and ORF1ab; the ABI Prism 7500 thermal cycler was used for PCR amplification (Life Technologies, I) \[[@bib1]\]. The results of the two tests were compared using Chi-square test.

We included naso-pharyngeal swabs (NPS, 123/162, 75.9%), bronchoalveolar lavage (BAL, 17/162, 10.5%), bronchoaspirate (12/162, 7.4%) and sputum (10/162, 6.2%). SARS-CoV-2 RNA was detected in 56/162 samples (34.6%) while FA showed the presence of viruses/bacteria in 63/162 (38.9%). FA results (28 samples with multiple microorganisms) identified bacteria in 53/63 patients (84.1%) and viruses in 22/63 (34.9%): *Staphylococcus aureus* (25/63, 39.7%), *Haemophilus influenzae* (15/63, 23.8%), group B Streptococci (6/63, 9.5%), Influenza A virus (5/63, 7.9%) and Influenza B, Coronaviruses, Rhino/Enterovirus (each 4/63, 6.3%).

FA was positive in 10/56 SARS-CoV-2 infected patients (17.8% vs. 50% in SARS-CoV-2 negative samples, Chi2 15.9, p\<0.001); interestingly, no other virus was found in SARS-CoV-2 positive patients (0% vs. 20.7%, Chi2 13.4, p\<0.001), but only *Staphylococcus aureus* (7/10), *Haemophilus influenzae* (2/10), *Escherichia coli* (2/10), *Moraxella catarrhalis*, group B Streptococci, *Klebsiella pneumoniae* and *Enterobacter cloacae* (1/10 each), most probably due to colonization or bacterial superinfection in 2 COVID-19 patients whose bronchoaspirate was positive for *Haemophilus influentiae* plus *Escherichia coli* and *Staphylococcus aureus*, respectively ([Table 1](#appsec1){ref-type="sec"}. Supplementary material). Soon after the onset of SARS-CoV-2 epidemics, the presence of other respiratory viruses declined and disappeared ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Figure 1

Our data are consistent with the absence of other respiratory virus coinfection in SARS-CoV-2 patients and a low bacterial coinfection rate mostly reflecting a carriage status.

Recently, several papers reported the possible concomitant presence of respiratory pathogens in subjects with COVID-19. Viral and bacterial pathogens have been described in case reports, case series and four cohorts: a low prevalence was reported (1.6-6.5%) with the exception of a recent paper by Kim et al. (24/116, 20.7%) \[[@bib2]\]~.~ Phenomena like viral interference, common receptor usage, different inoculum size or simply resource competition might explain why dual or multiple concurrent viral respiratory infections are rare \[[@bib3], [@bib4]\]. Few papers studied the clinical features of the co-infected patients: with the relevant exception of a child presenting with SARS-CoV-2/metapneumovirus/respiratory syncytial virus admitted to intensive care unit, no increased risk of severe disease was reported \[[@bib5]\]. In line with this, a 9-year old child included in the French Alps cluster was co-infected with SARS-CoV-2/rhino/enterovirus/influenza H1N1 and asymptomatic, but no secondary cases were found among his contacts \[[@bib6]\].

In conclusion, a multiplex PCR system for the rapid diagnosis of respiratory infections showed virtually no concomitant infection in patients positive for SARS-CoV-2 and, interestingly, with the spread of SARS-CoV-2, other respiratory pathogens seemed to vanish.
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